Heron Therapeutics reported increased net product sales of $34.7 million in the first quarter of 2024, compared to $29.6 million in the same period in 2023. The company saw growth in both its acute care and oncology care franchises. CEO Craig Collard expressed satisfaction with the financial performance, attributing it to revenue growth, improved margins, and reduced expenses. The company also made progress in training its sales representatives and commercial team on new products. Overall, Heron Therapeutics’ first quarter financial results reflected positive growth and efficiency in its business operations.
Source link
Heron Therapeutics announces increased net sales in first-quarter 2024 financial results
